HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amazon Flexes E-Commerce Heft By Imposing Quality-Control Requirements For Supplements

Executive Summary

Amazon requires firms selling supplements on its site in the US to demonstrate their products comply with FDA regulations for labeling and GMPs. Marketers that don’t submit documentation face removal of their products from the site.

You may also be interested in...



Amazon Testing Update Could, As FDA And Industry Want, Purge Bad Actors From Supplement Market

Latest update to Amazon’s screening policy for supplements requires showing sexual enhancement and weight loss products have been tested by third-party labs and lays out additional requirements for all supplement products.

US FDA Put On The Clock About NAC's Use As Dietary Ingredient After Amazon Ends Sales

Trade group asked FDA six months ago to reverse position it revealed in July 2020 that products containing NAC cannot be marketed as dietary supplements. After Amazon in May reported pulling NAC supplements from its site, CRN decided to ask again.

ED-Spiked Supplements Sold On Amazon Fill US FDA’s Recall Plate

Announcements for seven adulterated male sexual enhancement products were published across the work week, concluding with NANA Collection LLC’s products branded PremierZen Platinum 5000, found with undisclosed tadalafil, and Triple SupremeZen 3500, found to contain tadalafil and sildenafil, on 2 April.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel